Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AQST vs MNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNOV Captures Overall Composite Edge (50.2 HOLD vs 62.9 BUY), While AQST Leads 3–2 on Growth & Valuation Pillars

MNOV Overall Winner 6-Pillar Tally: AQST 3 – 2 MNOV (1 Tie) Matrix Metrics: AQST 5 – 5 MNOV

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (50.2/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 5–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. -114.1% operating margin) and revenue trajectory (+12.4% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs MNOV
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23
MNOV NASDAQ Head-to-Head Winner
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (AQST 3 – 2 MNOV)

Columns: Metric · AQST · MNOV
1. Valuation Multiples MNOV
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue 8.9x 42.5x
2. Growth & Scale AQST
Revenue Growth (YoY) -41.0% +12.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $49M $935,717
Market Cap $465.7M $65.1M
3. Profitability & Quality AQST
Gross Margin 65.3% 42.2%
Operating Margin -114.1% -1232.2%
Net Profit Margin -162.3% 0.0%
Return on Equity (ROE) 0.0% -24.8%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$41M -$9.1M
Cash Flow Margin -83.3% N/A
Net Cash / Leverage $32M Net Cash $25M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 87.9% (64th %ile) 140.1% (50th %ile)
Put/Call OI Skew 0.98x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (5) vs MNOV (5)
Institutional Metric AQST MNOV Criterion Row Edge
Market Capitalization
Scale
$465.7M $65.1M Larger Scale AQST
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY)
Growth
-41.0% +12.4% Higher Growth MNOV
Operating Margin (TTM)
Profitability
-114.1% -1232.2% Higher Margin AQST
Net Profit Margin
Profitability
-162.3% 0.0% Higher Margin MNOV
Return on Equity (ROE)
Capital Efficiency
0.0% -24.8% Higher ROE AQST
52-Week Range Position
Momentum
14% ($3–$7) 3% ($1–$4) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
0.89β · 56% Vol 0.59β · 38% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 50.2 / 100 (HOLD) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$49M $935,717 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% 42.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.9x EV/Rev N/M PEG · 42.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) -$9.1M ($25M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNOV +9.13 pp
AQST: -16.22% · MNOV: -7.09%
3M Horizon MNOV +13.54 pp
AQST: -27.92% · MNOV: -14.38%
6M Horizon MNOV +9.59 pp
AQST: -16.02% · MNOV: -6.43%
1Y Horizon MNOV +32.26 pp
AQST: -40.65% · MNOV: -8.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQST Revenue MNOV Revenue AQST Op. Margin MNOV Op. Margin Margin Leader
FY2018 $70M N/A -72.6% N/A AQST
FY2019 $50M N/A -100.1% N/A AQST
FY2020 $50M N/A -93.6% N/A AQST
FY2021 $50M $0M -68.2% -253.0% AQST
FY2022 $50M N/A -88.2% N/A AQST
FY2023 $50M $0M -29.9% -990.0% AQST
FY2024 $60M N/A -53.5% N/A AQST
FY2025 $40M $0M -159.5% -3242.5% AQST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs MNOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (50.2/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 5–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. -114.1% operating margin) and revenue trajectory (+12.4% vs. -41.0% YoY). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AQST leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQST cumulative revenue shifted -42.9% while MNOV shifted N/A. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.

MNOV screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus MNOV (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.